Last updated on April 2018

Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone


Brief description of study

The purpose of this study is to evaluate the effects of the addition of daratumumab to pomalidomide and dexamethasone in terms of progression-free survival in subjects with relapsed or refractory Multiple Myeloma.

Detailed Study Description

This is a multicenter, Phase 3, randomized, open-label study comparing daratumumab, pomalidomide and low-dose dexamethasone (DaraPomDex) with pomalidomide and low-dose dexamethasone (PomDex) in subjects with relapsed or refractory Multiple Myeloma who have received at least 1 prior treatment regimen with both lenalidomide and a proteasome inhibitor and have demonstrated disease progression. Subjects will be randomized in a 1:1 ratio to receive either DaraPomDex or PomDex. The original design of this study was to treat subjects with daratumumab for intravenous (IV) infusion (Dara IV); however, as of Amendment 1, all new subjects will be dosed subcutaneously with daratumumab co-formulated with recombinant human hyaluronidase rHuPH20 (hereafter referred to as Dara SC). Subjects who already began treatment with Dara IV (ie, prior to Amendment 1) will have the option to switch to Dara SC on Day 1 of any cycle starting with Cycle 3 or later for the remainder of their participation in the study, and they will be counted toward the total of 302 subjects. Subjects will receive treatment until disease progression or unacceptable toxicity. Drug administration and follow-up visits will occur more frequently for early cycles (e.g., weekly or bi-weekly). Disease evaluations will occur every cycle and consist mainly of measurements of myeloma proteins. Subject safety will be assessed throughout the study. The primary endpoint will be progression-free survival (PFS). Study end is anticipated at approximately 5 years after the last subject is randomized.

Clinical Study Identifier: NCT03180736

Find a site near you

Start Over

Antwerpen

Antwerpen, Belgium
  Connect »

Brussel

Brussel, Belgium
  Connect »

UZ Gent

Gent, Belgium
  Connect »

Yvoir

Yvoir, Belgium
  Connect »

Brno

Brno, Czechia
  Connect »

Ostrava

Ostrava, Czechia
  Connect »

Praha 2

Praha, Czechia
  Connect »

Odense

Odense, Denmark
  Connect »

Vejle

Vejle, Denmark
  Connect »

Freiburg

Freiburg, Germany
  Connect »

Hamburg

Hamburg, Germany
  Connect »

Heidelberg

Heidelberg, Germany
  Connect »

Kiel

Kiel, Germany
  Connect »

Schwerin

Schwerin, Germany
  Connect »

Ancona

Ancona, Italy
  Connect »

Bologna

Bologna, Italy
  Connect »

Brescia

Brescia, Italy
  Connect »

Milano

Milano, Italy
  Connect »

Roma

Roma, Italy
  Connect »

Torino

Torino, Italy
  Connect »

VU MC

Amsterdam, Netherlands
  Connect »

Erasmus MC

Rotterdam, Netherlands
  Connect »

T bingen

Tübingen, Germany
  Connect »

W rzburg

Würzburg, Germany
  Connect »

Belgrade

Belgrade, Serbia
  Connect »

Badalona

Badalona, Spain
  Connect »

Barcelona

Barcelona, Spain
  Connect »

Cebeci

Cebeci, Turkey
  Connect »

Gaziantep

Gaziantep, Turkey
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.